SI3555105T1 - Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2 - Google Patents
Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2Info
- Publication number
- SI3555105T1 SI3555105T1 SI201730488T SI201730488T SI3555105T1 SI 3555105 T1 SI3555105 T1 SI 3555105T1 SI 201730488 T SI201730488 T SI 201730488T SI 201730488 T SI201730488 T SI 201730488T SI 3555105 T1 SI3555105 T1 SI 3555105T1
- Authority
- SI
- Slovenia
- Prior art keywords
- phenylethylamino
- pyrimido
- oxazin
- compounds
- mutant idh1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662435283P | 2016-12-16 | 2016-12-16 | |
EP17822882.1A EP3555105B1 (en) | 2016-12-16 | 2017-12-08 | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
PCT/US2017/065246 WO2018111707A1 (en) | 2016-12-16 | 2017-12-08 | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3555105T1 true SI3555105T1 (sl) | 2020-12-31 |
Family
ID=60888651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201730488T SI3555105T1 (sl) | 2016-12-16 | 2017-12-08 | Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2 |
Country Status (36)
Country | Link |
---|---|
US (3) | US11001596B2 (sl) |
EP (2) | EP3763717B1 (sl) |
JP (1) | JP6793836B2 (sl) |
KR (1) | KR102276022B1 (sl) |
CN (2) | CN115109075A (sl) |
AU (2) | AU2017378060B2 (sl) |
CA (1) | CA3045303C (sl) |
CL (1) | CL2019001551A1 (sl) |
CO (1) | CO2019005287A2 (sl) |
CR (1) | CR20190252A (sl) |
CY (1) | CY1123577T1 (sl) |
DK (1) | DK3555105T3 (sl) |
DO (1) | DOP2019000163A (sl) |
EA (1) | EA036112B1 (sl) |
EC (1) | ECSP19042682A (sl) |
ES (2) | ES2941631T3 (sl) |
HR (1) | HRP20201882T1 (sl) |
HU (1) | HUE052067T2 (sl) |
IL (1) | IL267236B (sl) |
JO (1) | JOP20190142B1 (sl) |
LT (1) | LT3555105T (sl) |
MA (2) | MA53881A (sl) |
MD (1) | MD3555105T2 (sl) |
MX (1) | MX2019006830A (sl) |
MY (1) | MY197313A (sl) |
NZ (1) | NZ754115A (sl) |
PE (1) | PE20190977A1 (sl) |
PH (1) | PH12019501328A1 (sl) |
PL (1) | PL3555105T3 (sl) |
PT (1) | PT3555105T (sl) |
RS (1) | RS61108B1 (sl) |
SA (1) | SA519401897B1 (sl) |
SI (1) | SI3555105T1 (sl) |
TN (1) | TN2019000158A1 (sl) |
UA (1) | UA123640C2 (sl) |
WO (1) | WO2018111707A1 (sl) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3194383B1 (en) | 2014-09-19 | 2019-11-06 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
WO2016044789A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
WO2016044782A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
AU2015317327B9 (en) | 2014-09-19 | 2020-04-09 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
CA3040040A1 (en) | 2016-10-24 | 2018-05-03 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
PE20191105A1 (es) | 2016-12-16 | 2019-08-23 | Janssen Pharmaceutica Nv | Inhibidores de moleculas pequenas de lafamilia de quinasas jak |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
PE20190977A1 (es) * | 2016-12-16 | 2019-07-09 | Lilly Co Eli | Compuestos de 7-feniletilamino-4h-pirimido [4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e ihd2 mutantes |
LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
US20230000871A1 (en) * | 2019-11-08 | 2023-01-05 | Nerviano Medical Sciences S.R.L. | Gem-disubstituted heterocyclic compounds and their use as idh inhibitors |
EP4125915B1 (en) | 2020-03-23 | 2024-04-17 | Eli Lilly and Company | Combination therapy with a mutant idh inhibitor |
AU2021241471B2 (en) * | 2020-03-23 | 2023-12-14 | Eli Lilly And Company | Method for treating IDH1 inhibitor-resistant subjects |
IL296141A (en) * | 2020-03-23 | 2022-11-01 | Lilly Co Eli | Combined treatment with mutant idh inhibitor and bcl-2 inhibitor |
US20230174550A1 (en) * | 2020-06-28 | 2023-06-08 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Idh mutant inhibitor and use thereof |
EP4181927A1 (en) | 2020-07-20 | 2023-05-24 | Eli Lilly and Company | Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent |
CN113588768B (zh) * | 2021-05-18 | 2022-07-05 | 国家卫生健康委科学技术研究所 | 一种以分子图像方式定量组织内内源性代谢物的质谱方法 |
CN117460514A (zh) | 2021-06-09 | 2024-01-26 | 伊莱利利公司 | 用于治疗idh抑制剂耐药的对象的方法 |
CN117460512A (zh) | 2021-06-15 | 2024-01-26 | 微境生物医药科技(上海)有限公司 | Idh突变体抑制剂及其用途 |
WO2023018955A1 (en) | 2021-08-13 | 2023-02-16 | Eli Lilly And Company | Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2- enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one |
WO2023141087A1 (en) | 2022-01-19 | 2023-07-27 | Eli Lilly And Company | Combination therapy with a mutant idh inhibitor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140069235A (ko) * | 2011-09-27 | 2014-06-09 | 노파르티스 아게 | 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
MX2015012822A (es) * | 2013-03-14 | 2016-05-31 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. |
WO2014147586A1 (en) * | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
US10294206B2 (en) * | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
CA2979669A1 (en) * | 2015-04-24 | 2016-10-27 | Halliburton Energy Services, Inc. | Methods of fabricating ceramic or intermetallic parts |
WO2017019429A1 (en) * | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
WO2017213910A1 (en) * | 2016-06-06 | 2017-12-14 | Eli Lilly And Company | Mutant idh1 inhibitors |
PE20190977A1 (es) * | 2016-12-16 | 2019-07-09 | Lilly Co Eli | Compuestos de 7-feniletilamino-4h-pirimido [4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e ihd2 mutantes |
-
2017
- 2017-12-08 PE PE2019001077A patent/PE20190977A1/es unknown
- 2017-12-08 EP EP20189241.1A patent/EP3763717B1/en active Active
- 2017-12-08 CA CA3045303A patent/CA3045303C/en active Active
- 2017-12-08 PT PT178228821T patent/PT3555105T/pt unknown
- 2017-12-08 CR CR20190252A patent/CR20190252A/es unknown
- 2017-12-08 MA MA053881A patent/MA53881A/fr unknown
- 2017-12-08 MA MA47399A patent/MA47399B1/fr unknown
- 2017-12-08 US US16/349,873 patent/US11001596B2/en active Active
- 2017-12-08 SI SI201730488T patent/SI3555105T1/sl unknown
- 2017-12-08 EA EA201991161A patent/EA036112B1/ru not_active IP Right Cessation
- 2017-12-08 DK DK17822882.1T patent/DK3555105T3/da active
- 2017-12-08 MY MYPI2019003350A patent/MY197313A/en unknown
- 2017-12-08 NZ NZ754115A patent/NZ754115A/en unknown
- 2017-12-08 HU HUE17822882A patent/HUE052067T2/hu unknown
- 2017-12-08 CN CN202210758386.7A patent/CN115109075A/zh active Pending
- 2017-12-08 MX MX2019006830A patent/MX2019006830A/es unknown
- 2017-12-08 JO JOP/2019/0142A patent/JOP20190142B1/ar active
- 2017-12-08 PL PL17822882T patent/PL3555105T3/pl unknown
- 2017-12-08 EP EP17822882.1A patent/EP3555105B1/en active Active
- 2017-12-08 CN CN201780078017.0A patent/CN110072867B/zh active Active
- 2017-12-08 ES ES20189241T patent/ES2941631T3/es active Active
- 2017-12-08 TN TNP/2019/000158A patent/TN2019000158A1/en unknown
- 2017-12-08 KR KR1020197016855A patent/KR102276022B1/ko active IP Right Grant
- 2017-12-08 RS RS20201429A patent/RS61108B1/sr unknown
- 2017-12-08 AU AU2017378060A patent/AU2017378060B2/en active Active
- 2017-12-08 ES ES17822882T patent/ES2835281T3/es active Active
- 2017-12-08 LT LTEP17822882.1T patent/LT3555105T/lt unknown
- 2017-12-08 MD MDE20191188T patent/MD3555105T2/ro unknown
- 2017-12-08 JP JP2019532088A patent/JP6793836B2/ja active Active
- 2017-12-08 WO PCT/US2017/065246 patent/WO2018111707A1/en unknown
- 2017-12-08 UA UAA201905584A patent/UA123640C2/uk unknown
-
2019
- 2019-05-23 CO CONC2019/0005287A patent/CO2019005287A2/es unknown
- 2019-05-30 SA SA519401897A patent/SA519401897B1/ar unknown
- 2019-06-06 CL CL2019001551A patent/CL2019001551A1/es unknown
- 2019-06-11 IL IL267236A patent/IL267236B/en active IP Right Grant
- 2019-06-11 DO DO2019000163A patent/DOP2019000163A/es unknown
- 2019-06-13 PH PH12019501328A patent/PH12019501328A1/en unknown
- 2019-06-14 EC ECSENADI201942682A patent/ECSP19042682A/es unknown
-
2020
- 2020-10-29 AU AU2020260493A patent/AU2020260493B2/en active Active
- 2020-11-25 CY CY20201101122T patent/CY1123577T1/el unknown
- 2020-11-26 HR HRP20201882TT patent/HRP20201882T1/hr unknown
-
2021
- 2021-03-16 US US17/202,515 patent/US11649247B2/en active Active
- 2021-03-16 US US17/202,867 patent/US11629156B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3555105T1 (sl) | Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2 | |
EP3880208A4 (en) | KRAS G12C INHIBITORS | |
IL287223B1 (en) | kras g12c inhibitors and methods of using them | |
IL262867B (en) | kras g12c inhibitors | |
IL279363A (en) | PCSK9 antagonist compounds | |
HK1252821A1 (zh) | 用於治療具有rtk突變細胞的患者的組合物和方法 | |
ZA201802181B (en) | 2¿phenyl¿3,4¿dihydropyrrolo[2,1 ¿f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | |
EP3091984A4 (en) | Substituted benzoxazine and related compounds | |
EP3230234A4 (en) | Nitrification inhibitor compositions and methods for preparing the same | |
EP3810129A4 (en) | PCSK9 -ANTAGONISTIC BICYCLO COMPOUNDS | |
EP3240768A4 (en) | Nitrification inhibitor compositions and methods for preparing the same | |
EP3468555A4 (en) | ANTIMICROBIAL CONNECTIONS AND METHOD FOR USE THEREOF | |
HK1257555A1 (zh) | Tec激酶家族之抑制劑 | |
EP3552017A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS | |
PL3310784T3 (pl) | Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy | |
HUE060654T2 (hu) | Heterokondelzált piridonvegyületek és azok IDH-gátlóként történõ alkalmazása | |
EP3568018A4 (en) | COMPOUNDS AND METHOD OF USE | |
EP3191447A4 (en) | S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use | |
KR102383690B9 (ko) | 벤족사진계 혼합물, 및 이의 용도 | |
EP3364976A4 (en) | PIPERAZINYL-NORBENZOMORPHAN COMPOUNDS AND METHOD FOR USE THEREOF | |
EP3192513A4 (en) | 7-fluoro-8-chloro-5 -dibenzo[b,e][1,4]diazepine derivatives and use thereof | |
TH1501007226A (th) | สารประกอบ 6,7-ไดไฮโดรไพราโซโล[1,5-a]ไพราซีน-4(5H)-โอน และการใช้ของ สิ่งนั้นในฐานะเป็นสารยับยั้งแอลโลสเตอริกของ mGluR2 รีเซ็ปเตอร์ | |
AU2016901442A0 (en) | Methods and compositions for preventing and/or treating cataracts | |
AU2014903744A0 (en) | Nitrification inhibitors and formulations |